No Data
No Data
Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating
HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Maintains Target Price $7
Unlock the Full List